In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Veloxis Pharmaceuticals AS

www.veloxis.com

Latest From Veloxis Pharmaceuticals AS

Keeping Track Of The US FDA's Final Approvals Of 2018

A roundup of the US FDA's drug approvals in the final weeks of 2018.
Approvals Regulation

Deals Shaping The Medical Industry, July 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in June 2017.

Deals BioPharmaceutical

Appointments: Impax, Mylan, Eisai, Cipher, Hutchison and Arena Pharmaceuticals, Bridge Medicines and ProMIS

This week's round up of recent appointments includes new CEOs at Impax Laboratories, Cipher Pharmaceuticals and Bridge Medicines, and other senior appointments at Mylan, Eisai and Arena Pharmaceuticals.

Appointments BioPharmaceutical

European Notebook: All Change In The C-Suites; EMA PRIME Starts; French Experts Recommend Phase I Changes

Once-in-a-decade leadership changes stack up in Europe’s big pharma companies as the region aims for quicker and more certain drug development, although following a recent fatality an expert committee is advising caution during dose-escalation in Phase I studies.

BioPharmaceutical Europe
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
  • Therapeutic Areas
  • Cardiovascular
  • Immune Disorders
  • Alias(es)
  • LifeCycle Pharma AS
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Scandinavia
          • Denmark
  • Parent & Subsidiaries
  • Veloxis Pharmaceuticals AS
  • Senior Management
  • Craig A Collard, Pres. & CEO
    Ira Duarte, CFO
    Alastair McEwan, EVP, COO
    Mark Hensley, Chief Commercial Officer
  • Contact Info
  • Veloxis Pharmaceuticals AS
    Phone: (45) 70 33 33 00
    Amerika Plads 37
    København , 2100
    Denmark
Advertisement
Advertisement
UsernamePublicRestriction

Register